Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Launches Lab Services Business

NEW YORK, March 10 - PerkinElmer said today that it is adding a professional services business unit to its life sciences group.


The new business, called OneSource, will offer an enhanced level of service and support for PerkinElmer's life science customers, according to the company. The business unit, which comprises more than 1,000 PerkinElmer engineers operating in 120 countries, will provide on-demand repairs, validation certification, education, and training for the company's analytical instruments as well as third-party systems. 


John Danner, formerly vice president and general manager of PerkinElmer Life Sciences, will head up the OneSource business.


In an interview with GenomeWeb's sister publication Genome Technology in November, Peter Coggins, president of PerkinElmer Life and Analytical Sciences, said the company was evaluating ways in which it could "drive service as a business." At the time, he said that PerkinElmer had already signed a services contract with a pharmaceutical company worth over $1 million.


The company said today that it expects to launch new service offerings throughout the year "to fully enable these comprehensive service partnerships."

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.